Amedisys (AMED) PT Raised to $350 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
RBC Capital analyst Frank Morgan raised the price target on Amedisys (NASDAQ: AMED) to $350.00 (from $335.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Camtek (CAMT) PT Lowered to $140 at Stifel
- Datadog (DDOG) PT Lowered to $260 at BTIG
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
